Good evening :)
Place Order
Add to Watchlist

Biocon Ltd

BIOCON

Biocon Ltd

BIOCON
Health CareBiotechnology
MidcapWith a market cap of ₹46,335 cr, stock is ranked 185
Moderate RiskStock is 2.73x as volatile as Nifty
377.152.38% (-9.20)
377.152.38% (-9.20)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareBiotechnology
MidcapWith a market cap of ₹46,335 cr, stock is ranked 185
Moderate RiskStock is 2.73x as volatile as Nifty

How to use scorecard? Learn more

Health CareBiotechnology
MidcapWith a market cap of ₹46,335 cr, stock is ranked 185
Moderate RiskStock is 2.73x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
56.171.790.13%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.006.360.53%

Forecast & Ratings

Detailed Forecast 
69%
Analysts have suggested that investors can buy this stock

from 16 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.

PE Ratio
-45.21
1Y Return
9.81%
Buy Reco %
—
PE Ratio
180.19
1Y Return
6.19%
Buy Reco %
100.00
PE Ratio
-2,054.78
1Y Return
159.85%
Buy Reco %
—
PE Ratio
48.79
1Y Return
139.59%
Buy Reco %
—
PE Ratio
82.79
1Y Return
30.61%
Buy Reco %
—
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 21.69%, vs industry avg of 19.04%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 76.57% to 84.66%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 2.46%, vs industry avg of 2.04%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue3,716.704,064.504,350.905,854.306,529.407,410.208,396.7011,550.1015,621.2016,088.30
Raw Materialssubtract1,330.901,515.601,677.802,106.302,190.302,533.802,975.003,817.205,754.6011,799.80
Power & Fuel Costsubtract184.70156.40189.00239.80246.10270.30316.40414.80388.90
Employee Costsubtract610.10747.00931.101,165.301,458.801,741.001,880.102,181.002,664.10
Selling & Administrative Expensessubtract524.50540.10519.30846.70952.701,041.701,158.101,338.601,725.80
Operating & Other expensessubtract37.20-47.50-22.90-237.40-121.60-17.10202.201,369.301,019.40
Depreciation/Amortizationsubtract248.70277.20385.10447.80552.20715.10814.201,113.101,568.801,657.70
Interest & Other Itemssubtract29.3026.0061.5070.9064.9057.7067.60419.00974.40912.00
Taxes & Other Itemssubtract200.90237.60237.60309.60437.80327.20334.70434.40502.70914.50
EPS4.595.103.107.546.236.175.403.858.526.70
DPS0.830.500.500.500.000.000.501.500.500.50
Payout ratio0.180.100.160.070.000.000.090.390.060.07

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Apr 29PDF
Apr 28PDF
Mar 1PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

May 24PDF
Feb 17PDF
Nov 15PDF
Jul 27PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Biocon Ltd44.191.790.13%
Onesource Specialty Pharma Ltd-45.2144.37—
Sai Life Sciences Ltd180.1915.30—
Panacea Biotec Ltd-2,054.782.85—

Price Comparison

Compare BIOCON with any stock or ETF
Compare BIOCON with any stock or ETF
BIOCON
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding60.64%8.58%6.78%5.66%18.34%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

SepDec '23MarJunSepDec '247.96%6.55%5.63%5.90%5.93%5.66%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Biocon Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.3122%1.46%-0.00%19/103 (0)
1.0192%1.84%0.04%42/74 (-23)
0.7841%1.09%-0.01%25/147 (+6)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 5, 2024

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jul 5, 2024

Cash Dividend

Ex DateEx DateJul 7, 2023

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Jul 7, 2023

Cash Dividend

Ex DateEx DateJun 30, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jun 30, 2022

Cash Dividend

Ex DateEx DateJul 18, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jul 18, 2019

Cash Dividend

Ex DateEx DateJul 19, 2018

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Jul 19, 2018

News & Opinions
Spotlight
Biocon Ltd soars 1.76%, rises for third straight session

Biocon Ltd rose for a third straight session today. The stock is quoting at Rs 397.1, up 1.76% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.41% on the day, quoting at 23600.05. The Sensex is at 77920.62, down 0.45%. Biocon Ltd has added around 3.86% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 32.7 lakh shares today, compared to the daily average of 64.56 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 396.75, up 1.48% on the day. Biocon Ltd is up 36.81% in last one year as compared to a 7.61% gain in NIFTY and a 18.78% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending December 24.Powered by Capital Market - Live

4 days agoCapital Market - Live
Spotlight
Biocon records PAT of Rs 25 crore in Q3; EBITDA falls 47% YoY

Revenue from operations fell by 3% YoY to Rs 3,821 crore during the period under review. The company's Generics business, comprising of APIs & generic formulations, has recorded revenues of Rs 686 crore in Q3 FY25, down 2% YoY. Biocon Biologics, which houses Biocon's biosimilars business, has reported 8% YoY fall in revenue to Rs 2,289 crore. Syngene, which is the Research services division of Biocon, has registered 11% increase in revenue to Rs 944 crore in the third quarter as compared with the same period last year. The company's Research & Development expenses added up to Rs 199 crore in Q3 FY25, down 40% YoY. EBITDA declined by 47% to Rs 787 crore in Q3 FY25 from Rs 1,492 crore in Q3 FY24. Profit before tax in Q3 FY25 stood at Rs 156 crore, down by 81% from Rs 753 crore in Q3 FY24. Kiran Mazumdar-Shaw, chairperson, Biocon Group, said: 'The Biocon Group reported Q3 FY25 operating revenue of Rs 3,821 crore, with performance driven by a sustained double-digit growth of 14% on a like-for-like basis in Biosimilars and a return to growth in Research services, which grew by 11%. The growth trajectory is clearly visible with sequential growth across all the three business segments this quarter. EBITDA at Rs 787 crore, reported a growth of 16% while profit before tax and exceptional items at Rs 138 crore, improved significantly from a marginal loss last year, on a like-for-like basis. Syngene's return to growth, combined with global approvals for bUstekinumab and European approval for gLiraglutide, will pave the way for launches and drive growth in Q4 and beyond. These developments will strategically position the Biocon Group for enhanced long-term growth.' Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The scrip added 1.96% to currently trade at Rs 364.15 on the BSE. Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Biocon consolidated net profit declines 96.20% in the December 2024 quarter

Net profit of Biocon declined 96.20% to Rs 25.10 crore in the quarter ended December 2024 as against Rs 660.00 crore during the previous quarter ended December 2023. Sales rose 6.32% to Rs 3773.00 crore in the quarter ended December 2024 as against Rs 3548.70 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales3773.003548.70 6 OPM %19.9325.44 - PBDT563.201201.50 -53 PBT137.80787.00 -82 NP25.10660.00 -96 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Board of Biocon approves issuance of commercial paper of Rs 570 cr

The Board of Biocon at its meeting held on 27 January 2025 has approved the issuance of commercial paper of Rs 570 crore on private placement basis. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Biocon achieves 6 point increase in its S&P Global ESG score to 69 for 2024

Biocon announced its Environmental, Social and Governance (ESG) scores as assessed by S&P Global's Corporate Sustainability Assessment (CSA) for 2024. Biocon achieved a notable improvement with an S&P Global ESG Score of 69 in 2024, up 6 points from 63 in 2023. This places the Company in the 98th percentile among its global biotechnology industry peers. Biocon achieved an ESG Score of 76 in the Environmental Dimension, 74 in the Social Dimension, and 62 in the Governance & Economic Dimension. Biocon's subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score core of 53Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Biocon to convene board meeting

Biocon will hold a meeting of the Board of Directors of the Company on 27 January 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Live Market Update
Nifty trades above 23,200; consumer durables shares advance

The key equity indices traded with decent gains in mid-morning trade. The Nifty traded above the 23,200 level after hitting the day's low of 23,090.65 in early trade. Consumer durables shares advanced after declining in past two consecutive trading sessions. Trading could be volatile due to weekly F&O series expiry today. At 11:30 IST, the barometer index, the S&P BSE Sensex rose 177.93 points or 0.23% to 76,582.01. The Nifty 50 index added 64.65 points or 0.28% to 23,220. The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index jumped 1.83% and the S&P BSE Small-Cap index rallied 1.16%. The market breadth was strong. On the BSE, 2,408 shares rose and 1,260 shares fell. A total of 175 shares were unchanged. Politics: The JD(U) on Wednesday sacked its Manipur unit president, Ksh. Biren Singh, in an effort to quell growing speculation about its ties with the BJP. Party's national spokesperson Rajiv Ranjan told the media Singh's removal was due to indiscipline and asserted that the party would continue to support the BJP-led government in the northeastern state. Ranjan affirmed that the JD(U) remains committed to supporting the BJP-led NDA, not just in Manipur but across the country. Ranjan's remark came shorty after Ksh Biren Singh claimed that the party had withdrawn support to the BJP-led Biren Singh government and informed its decision to governor Ajay Kumar Bhalla. The state unit chief had also claimed that the lone JDU MLA in the state, Md Abdul Nasir, will sit in the opposition benches. IPO Update: The initial public offer (IPO) of Denta Water and Infra Solutions received bids for 13,37,67,000 shares as against 52,50,000 shares on offer, according to stock exchange data at 11:15 IST on 23 January 2024. The issue was subscribed to 25.48 times. The issue opened for bidding on 22 January 2024 and it will close on 24 January 2024. The price band of the IPO is fixed between Rs 279 and Rs 294 per share. An investor can bid for a minimum of 50 equity shares and in multiples thereof. Buzzing Index: The Nifty Consumer Durables index jumped 1.93% to 38,482. The index dropped 4.86% in past trading sessions. Amber Enterprises India (up 9.80%), Dixon Technologies (India) (up 3.03%), Voltas (up 2.08%), Havells India (up 2.08%), Whirlpool of India (up 1.94%), Bata India (up 1.74%), Kalyan Jewellers India (up 1.58%), Titan Company (up 1.24%), Crompton Greaves Consumer Electricals (up 1.22%) and Kajaria Ceramics (up 1.02%) advanced. On the other hand, V-Guard Industries (down 0.66%), Cera Sanitaryware (down 0.29%) and Rajesh Exports (down 0.1%) edged lower. Stocks in Spotlight: Biocon advanced 1.83% after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis. Bharat Petroleum Corporation (BPCL) slipped 1.33%. The company has reported a 36.85% jump in standalone net profit to Rs 4,649.20 crore in Q3 FY25 as against Rs 3,397.27 crore posted in Q3 FY24. Net sales (excluding excise duty) declined 2.02% year on year (YoY) to Rs 1,13,135.8 crore in the December 2024 quarter. Hindustan Unilever (HUL) declined 1.29%. The company has reported a 19.13% jump in standalone net profit to Rs 3,001 crore in Q3 FY25 as compared with Rs 2,519 crore in corresponding quarter last year. Revenue from operations rose 1.79% to Rs 15,195 crore in Q3 FY25 as compared with Rs 14,928 crore in Q3 FY24. Global Markets: Most Asian stocks climbed on Thursday, buoyed by a rally on Wall Street driven by optimism over increased spending on artificial intelligence (AI). However, Asian investors remain cautious as they assess the implications of US President Donald Trump's early days in office, which have sent mixed signals. While Trump reiterated tariff threats against China, fears of an escalation in the trade war have largely been avoided, leaving the world's second-largest economy somewhat unscathed for now. In China, investors are considering additional measures from Beijing to stabilize its stock market. On Wednesday, the government introduced a series of policies, including plans to increase the portion of pension funds that can be invested in listed companies, aiming to shore up market confidence. South Korea's economy grew by 0.1% quarter-on-quarter in the final three months of 2024, according to preliminary data from the central bank. On a year-on-year basis, GDP growth slowed to 1.2% from 1.5%, reflecting challenges in the broader economic environment. Meanwhile, Japan posted a surprising trade surplus of 130.9 billion yen ($840 million) in December, beating expectations for a deficit of 55 billion yen. This marked a significant turnaround from November's 110.3 billion yen deficit, supported by strong exports, according to government data released Thursday. In the US, the S&P 500 came close to a record high on Wednesday, boosted by a surge in tech stocks and AI-related companies. The rally followed President Trump's announcement of a $500 billion initiative to enhance domestic AI development. Netflix shares soared nearly 10% after the company reported a record-breaking addition of 19 million new subscribers in Q4 2024, surpassing market expectations by a wide margin. The S&P 500 briefly touched an all-time high of 6,100.81 points before trimming gains to close 0.6% higher at 6,086.28 points. The NASDAQ Composite gained 1.3% to reach 20,009.34 points, while the Dow Jones Industrial Average edged up 0.3%. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Biocon gains as board to mull fund raising on Jan 27

The company will raise funds through the issuance of commercial papers (CPs) or through any other mode. Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The company reported a consolidated net loss of Rs 16 crore in Q2 FY25 as against a net profit of Rs 126 crore in Q2 FY24. Revenue from operations rose by 4% YoY to Rs 3,590 crore during the quarter. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Biocon surges after Malaysian facility gets classified as VAI by the US FDA

The aforementioned action from the American drug regulator relates to the cGMP inspection conducted by the agency between 15th and 27th of September 2024. The inspection scope had included several biologics manufacturing units comprising one drug substance and one drug product manufacturing units, one medical device assembly unit, one analytical quality control laboratory, two microbiological control laboratories and two warehouses. Biocon Biologics (BBL) is a fully integrated global biosimilars company and the subsidiary of Biocon. Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
Biocon rises after biosimilars arm gets regulatory approval from Japan Health Authority for Ustekinumab

The approved drug is a biosimilar of the reference product Stelara (Ustekinumab). Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA). The biosimilar Ustekinumab has been developed and manufactured by the company and will be commercialized and marketed in Japan by the company's exclusive commercial partner, Yoshindo Inc. In August this year, Biocon Biologics had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan, upon regulatory approval. Biocon Biologics (BBL) is a fully integrated global biosimilars company and the subsidiary of Biocon. Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The company reported a consolidated net loss of Rs 16 crore in Q2 FY25 as against a net profit of Rs 126 crore in Q2 FY24. Revenue from operations rose by 4% YoY to Rs 3,590 crore during the quarter. Powered by Capital Market - Live

1 month agoCapital Market - Live